Publicaciones en colaboración con investigadores/as de Complexo Hospitalario Universitario da Coruña (13)

2023

  1. Dual neoadjuvant blockade plus chemotherapy versus monotherapy for the treatment of women with non-metastatic HER2-positive breast cancer: a systematic review and meta-analysis

    Clinical and Translational Oncology, Vol. 25, Núm. 4, pp. 941-958

2018

  1. Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer: a GEICAM/9906 substudy

    Clinical and Translational Oncology, Vol. 20, Núm. 12, pp. 1548-1556

2014

  1. Predicting response and survival in chemotherapy-treated triple-negative breast cancer

    British Journal of Cancer, Vol. 111, Núm. 8, pp. 1532-1541

  2. Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: Results from the GEICAM/2006-14 trial

    British Journal of Cancer, Vol. 110, Núm. 5, pp. 1139-1147

2012

  1. A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study

    Breast Cancer Research and Treatment, Vol. 136, Núm. 2, pp. 487-493

  2. Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: Results from the GEICAM/2006-03, a multicenter, randomized, phase-II study

    Annals of Oncology, Vol. 23, Núm. 12, pp. 3069-3074

2010

  1. Adjuvant docetaxel for high-risk, node-negative breast cancer

    New England Journal of Medicine, Vol. 363, Núm. 23, pp. 2200-2210

  2. Current controversies in the management of breast cancer

    Clinical and Translational Oncology, Vol. 12, Núm. 4, pp. 278-286

  3. Erratum: Current controversies in the management of breast cancer (Clinical and Translational Oncology 12:4 (278-286))

    Clinical and Translational Oncology

2008

  1. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer

    Journal of the National Cancer Institute, Vol. 100, Núm. 11, pp. 805-814

  2. Time-to-progression in breast cancer: A stratification model for clinical trials

    Breast, Vol. 17, Núm. 3, pp. 239-244

2007

  1. Recomendaciones para la prevención, diagnóstico y tratamiento de osteonecrosis de los maxilares (ONM) en pacientes con cáncer tratados con bisfosfonatos

    Medicina Oral, Patologia Oral y Cirugia Bucal, Vol. 12, Núm. 4, pp. 279-283

2006

  1. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): Impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen

    Annals of Oncology, Vol. 17, Núm. 8, pp. 1205-1212